

**Sun Pharmaceutical Industries Limited**

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.

Tel.: (91-22) 4324 4324

Fax: (91-22) 4324 4343

Website: [www.sunpharma.com](http://www.sunpharma.com)

Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)

CIN: L24230GJ1993PLC019050



September 10, 2024

**National Stock Exchange of India Limited**  
**Scrip Symbol: SUNPHARMA**

**BSE Limited**  
**Scrip Code: 524715**

**Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Regulatory Order**

This is to inform that the Company has received an order passed by statutory authority. Relevant details, as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, are provided in Annexure A.

The Company shall take appropriate action in the matter.

For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)

**Company Secretary and Compliance Officer**

ICSI Membership No.: A23983

**Sun Pharmaceutical Industries Limited**

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.

Tel.: (91-22) 4324 4324

Fax: (91-22) 4324 4343

Website: [www.sunpharma.com](http://www.sunpharma.com)

Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)

CIN: L24230GJ1993PLC019050

**Annexure A****Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015**

Sl. No.	Particulars	Information																														
a)	Name of the authority	Regional Director, North Western Region, Ministry of Corporate Affairs																														
b)	Nature and details of the action(s) taken, initiated, or order(s) passed	<p>Adjudication Orders passed under Section 454 for alleged violations under certain provisions of the Companies Act, 2013. The total penalty imposed on the Company and its Directors for all the matters (as detailed at point no. (d) below) together is INR 10,70,000 (Rupees Ten Lakhs Seventy Thousand only) as follows,</p> <table border="1"> <thead> <tr> <th colspan="5">Penalty Amount in INR</th> </tr> <tr> <th></th> <th>(1)</th> <th>(2)</th> <th>(3)</th> <th>(4)</th> </tr> </thead> <tbody> <tr> <td>Sun Pharmaceutical Industries Limited</td> <td>2,00,000</td> <td>5,000</td> <td>2,00,000</td> <td>2,00,000</td> </tr> <tr> <td>Mr. Dilip Shanghvi</td> <td>50,000</td> <td>5,000</td> <td>50,000</td> <td>50,000</td> </tr> <tr> <td>Mr. Sailesh Desai</td> <td>50,000</td> <td>5,000</td> <td>50,000</td> <td>50,000</td> </tr> <tr> <td>Mr. Sudhir Valia</td> <td>50,000</td> <td>5,000</td> <td>50,000</td> <td>50,000</td> </tr> </tbody> </table>	Penalty Amount in INR						(1)	(2)	(3)	(4)	Sun Pharmaceutical Industries Limited	2,00,000	5,000	2,00,000	2,00,000	Mr. Dilip Shanghvi	50,000	5,000	50,000	50,000	Mr. Sailesh Desai	50,000	5,000	50,000	50,000	Mr. Sudhir Valia	50,000	5,000	50,000	50,000
Penalty Amount in INR																																
	(1)	(2)	(3)	(4)																												
Sun Pharmaceutical Industries Limited	2,00,000	5,000	2,00,000	2,00,000																												
Mr. Dilip Shanghvi	50,000	5,000	50,000	50,000																												
Mr. Sailesh Desai	50,000	5,000	50,000	50,000																												
Mr. Sudhir Valia	50,000	5,000	50,000	50,000																												
c)	Date of receipt of direction or order, including any ad-interim or interim orders or any other communication from the authority	September 9, 2024																														
d)	Details of the violation(s)/ contravention(s) Committed or alleged to be committed	<p>This matter pertains to the earlier investigation carried out by SEBI, in which a Settlement was reached with SEBI in February 2021 without admission or denial of guilt; however, the Ministry of Corporate Affairs also initiated an investigation in parallel in 2019.</p> <p>The adjudication orders pertain to the following technical /procedural matters.</p> <p>(1) Non-filing of the Form MGT-14 in the FY 2014-15, under Section 117 of the Companies Act, 2013 in respect of board approval under section 179(3)(g) for revision of financial statements pursuant to order of the Honorable High Court of Ahmedabad, approving the scheme of arrangement.</p>																														

## Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.

Tel.: (91-22) 4324 4324

Fax: (91-22) 4324 4343

Website: [www.sunpharma.com](http://www.sunpharma.com)

Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)

CIN: L24230GJ1993PLC019050



		<p>(2) Non-enclosure of full set of Memorandum of Association after alteration under Section 13, 16 and 97 of the Companies Act, 1956 which was not possible due to restriction on the size of MCA filings, in the FY 2010-11.</p> <p>(3) Non-filing of resolution under Section 180(1)(a) of the Companies Act, 2013 in separate sections in Form MGT-14 in the FY 2014-15</p> <p>(4) Non-filing of Form MGT-14 in the FY 2014-15 relating to ESOP Schemes of the erstwhile Ranbaxy Laboratories Limited under Section 117 of the Companies Act, 2013 post merger</p>
e)	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There is no material impact on the Company's financial, operation or other activities.